- ￥800 - 2500
- Sino Biological
- 北京
- 40589-T62
- 2025年09月19日
- WB,ELISA
- Rabbit
- 兔
企业认证
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 免疫原：
Recombinant SARS-CoV-2 / 2019-nCoV Spike Protein (Catalog#40589-V08B1)
- 亚型：
Rabbit IgG
- 形态：
液体
- 保存条件：
在-20℃ to -80℃
- 克隆性：
PAb
- 适应物种：
兔
- 保质期：
12个月
- 抗原来源：
40589-V08B1
- 目录编号：
40589-T62
- 级别：
免疫学试剂
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 宿主：
Rabbit
- 应用范围：
WB,ELISA
- 浓度：
WB: 1:1000-1:5000;ELISA: 1:5000-1:10000
- 靶点：
Spike
- 抗体英文名：
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit PAb, Antigen Affinity Purified
- 抗体名：
新冠病毒 Spike 兔多抗
- 规格：
20 µL/100 µL
| 规格： | 20 µL | 产品价格： | ￥800.0 |
|---|---|---|---|
| 规格： | 100 µL | 产品价格： | ￥2500.0 |
Coronavirus spike|Coronavirus spike antibody|Coronavirus spike抗体|Anti-2019-nCoV 兔多抗（产品说明）
抗体种属：2019-nCoV
抗体靶点：Spike
抗体应用：WB,ELISA
抗原货号：40589-V08B1
抗原描述：Recombinant SARS-CoV-2 / 2019-nCoV Spike Protein (Catalog#40589-V08B1)
抗体宿主：Rabbit
抗体Ig类型：Rabbit IgG
抗体纯化方法：Protein A & Antigen Affinity
抗体制备：Produced in rabbits immunized with purified, recombinant SARS-CoV-2 / 2019-nCoV Spike Protein (S1+S2 ECD)(Catalog#40589-V08B1; YP_009724390.1; Val16-Pro1213). The specific IgG was purified by SARS-CoV-2 / 2019-nCoV Spike affinity chromatography.
抗体特异性：SARS-CoV-2 / 2019-nCoV Spike
抗体保存：This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. 
点击图片，了解更多促销信息
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验1, Zhu S, et al. Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry.Science China. Life sciences, PubMed ID: 34431042
2, Bao L, et al. Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.Journal of applied microbiology, PubMed ID: 34706134
3, Ren W, et al. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.mBio, PubMed ID: 35266815
4, Petersen JD, et al. The Delta variant SARS-CoV-2 spike protein uniquely promotes aggregation of pseudotyped viral particles.bioRxiv : the preprint server for biology, PubMed ID: 35441171
5, Rossotti MA, et al. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models.Communications biology, PubMed ID: 36085335
6, Yu D, et al. Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication.Molecular therapy : the journal of the American Society of Gene Therapy, PubMed ID: 36945774
7, Tan S, et al. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants.Science bulletin, PubMed ID: 37993332
8, Sun Y, et al. Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity.Cell reports. Medicine, PubMed ID: 38029750
9, Lu J, et al. Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.Emerging microbes & infections, PubMed ID: 38377136
10, Takeishi A, et al. Genetic engineering employing MPB70 and its promoter enables efficient secretion and expression of foreign antigen in bacillus Calmette Guérin (BCG) Tokyo.Microbiology and immunology, PubMed ID: 38294180
技术资料暂无技术资料 索取技术资料
